Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan.

Abstract

Ravulizumab is a long-acting C5 inhibitor available for treating paroxysmal nocturnal hemoglobinuria (PNH). Post-marketing surveillance (PMS) was implemented following its approval in September 2019 in Japan. We report safety data obtained through to December 2021 for 218 patients and effectiveness data for 194 patients (182 switched from eculizumab and 12 complement inhibitor-naïve). Over a median follow-up of 74.4 weeks, 193 adverse events (AEs) were reported in 66/218 patients (30.3%; incidence 72.73/100 patient-years). The two most frequent AEs were anemia and pyrexia (each 3.01/100 patient-years). The incidence of serious AEs was 36.93/100 patient-years. In patients who switched from eculizumab, lactate dehydrogenase (LDH) and hemoglobin (Hb) levels were maintained over 26 weeks of ravulizumab treatment. In complement inhibitor-naïve patients, LDH decreased significantly and Hb increased significantly over 26 weeks of ravulizumab treatment. These data for Japanese patients with PNH who were naïve to complement inhibitors and patients who switched from eculizumab show that the safety and effectiveness of ravulizumab are consistent with the published clinical trial data. However, transfusion independence was less likely in patients with bone marrow failure. Further follow-up data from this PMS will help to elucidate the long-term clinical safety and effectiveness of ravulizumab for treating PNH.

• Authors: Kensuke Usuki, Takayuki Ikezoe, Ken Ishiyama, Yoshinobu Kanda, Akihiko Gotoh, Hideo Hayashi, Akihiko Shimono, Akiyo Kitajima, Naoshi Obara, Jun-Ichi Nishimura
• Journal: International journal of hematology (Int J Hematol) Vol. 118 Issue 3 Pg. 311-322 (Sep 2023) ISSN: 1865-3774 [Electronic] Japan
• PMID: 37477863 (Publication Type: Journal Article)
• Copyright: © 2023. Japanese Society of Hematology.

Chemical References

• ravulizumab
• Complement Inactivating Agents
• L-Lactate Dehydrogenase

Topics

• Humans
• Hemoglobinuria, Paroxysmal (drug therapy)
• Japan (epidemiology)
• Complement Inactivating Agents (adverse effects)
• L-Lactate Dehydrogenase
• Product Surveillance, Postmarketing
• Hemolysis